Applied DNA’s Platform Empowers President Trump’s Anti-Counterfeiting Memorandum Signed Today to Protect American Consume...
April 03 2019 - 2:05PM
Business Wire
Applied DNA Sciences Inc. (NASDAQ: APDN), a leader in PCR-based
DNA manufacturing for product authenticity and traceability
solutions, announced its recognition of and alignment with the
Memorandum signed today by President Donald Trump to help protect
American consumers, manufacturers, and factory workers from
counterfeiting.
Applied DNA is using its patented molecular tagging to fight
illegal counterfeiting across a variety of industries for its
customer base including retailers, consumer product manufacturers
of textiles and pharmaceuticals, and the United States Government,
assisting in securing the Department of Defense (DoD)
supply chain.
Specific programs to provide commercial, law enforcement and DoD
counterfeit risk mitigation include:
- Applied DNA has definitive agreements
with leading manufacturers for products sold at retail in Bed Bath
& Beyond, Costco, Amazon and other retail stores and online
commerce sites.
- Since 2011, the Company’s technology
has been protecting microcircuits for DoD with nearly a million
parts tagged.
- Development contracts since 2014 have
engaged Defense Logistics Agency (DLA), the Army, USDA, Missile
Defense Agency and other trade and intelligence agencies to protect
critical industrial components such as bearings, lubricants,
gaskets, electronics equipment and packaging.
- Currently running is an
anti-counterfeiting technology-expanding competitive-bid
development contract awarded in June 2017, funded by the Office of
the Secretary of Defense on behalf of DLA, with collaboration from
the Army’s Combat Capabilities Development Command (CCDC) Chemical
Biological Center.
- In European courtrooms, the Company’s
award-winning technology has been used as evidence and its
forensics scientists have testified as expert witness in support of
cases which have resulted in convictions of 138 offenders for a
total of 670 sentence-years in crimes related to ATM cash thefts,
automobile-parts theft and resale online as new, and law
enforcement stings including drug enforcement.
Applied DNA’s approach to authenticate and protect global supply
chains is based on the Company’s patented CertainT® platform of
Tag, Test and Track, which provides benefits in
anti-counterfeiting, diversion, IP protection and claims
substantiation such as country of origin and sustainability.
“We are happy to see attention at the Federal level on this
global issue to protect American consumers and American
manufacturers and brands,” stated Dr. James Hayward, president and
CEO of Applied DNA. “Our CertainT platform is proven to provide
transparency, traceability and trust across the global marketplace
and can empower the President’s directive.”
NOTE: Dr. James Hayward is available for
interviews.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to its history of net losses, limited financial
resources, limited market acceptance and various other factors
detailed from time to time in Applied DNA’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
18, 2018 and our subsequent quarterly report on Form 10-Q filed on
February 7, 2019, and other reports we file with the SEC, which are
available at www.sec.gov. Applied DNA undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to
reflect the occurrence of unanticipated events, unless otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190403005793/en/
investor contact: Sanjay M. Hurry, 212-838-3777,
shurry@lhai.commedia contact: Meryl Rader, 781-639-4924,
meryl@cgprpublicrelations.comprogram contact: MeiLin Wan,
631-240-8849, meilin.wan@adnas.comweb: www.adnas.comTwitter:
@apdn
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024